Insider Selling: Inogen Inc. (INGN) CEO Sells 7,089 Shares of Stock
Inogen Inc. (NASDAQ:INGN) CEO Raymond Huggenberger sold 7,089 shares of the stock in a transaction that occurred on Monday, October 17th. The stock was sold at an average price of $56.24, for a total value of $398,685.36. Following the completion of the sale, the chief executive officer now directly owns 8,342 shares of the company’s stock, valued at $469,154.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Raymond Huggenberger also recently made the following trade(s):
- On Monday, August 15th, Raymond Huggenberger sold 20,747 shares of Inogen stock. The stock was sold at an average price of $57.48, for a total value of $1,192,537.56.
Shares of Inogen Inc. (NASDAQ:INGN) traded down 0.54% during mid-day trading on Wednesday, hitting $57.46. The company had a trading volume of 105,210 shares. The firm has a 50-day moving average price of $59.11 and a 200-day moving average price of $52.39. Inogen Inc. has a 52 week low of $28.81 and a 52 week high of $61.87. The firm has a market capitalization of $1.15 billion, a PE ratio of 84.50 and a beta of 0.88.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.20 by $0.05. The firm earned $54.57 million during the quarter, compared to analyst estimates of $52.44 million. Inogen had a return on equity of 9.50% and a net margin of 7.86%. Inogen’s revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.17 EPS. Equities analysts forecast that Inogen Inc. will post $0.63 earnings per share for the current year.
Several analysts have recently commented on INGN shares. JPMorgan Chase & Co. increased their price objective on Inogen from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, August 5th. Needham & Company LLC reissued a “strong-buy” rating and issued a $64.00 price objective (up from $58.00) on shares of Inogen in a research note on Sunday, August 7th. Stifel Nicolaus downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $58.50.
Several large investors have recently bought and sold shares of the company. TIAA CREF Investment Management LLC increased its position in shares of Inogen by 0.9% in the first quarter. TIAA CREF Investment Management LLC now owns 100,661 shares of the medical technology company’s stock valued at $4,528,000 after buying an additional 940 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Inogen by 4.8% in the first quarter. JPMorgan Chase & Co. now owns 444,075 shares of the medical technology company’s stock valued at $19,975,000 after buying an additional 20,525 shares in the last quarter. Royce & Associates LP increased its position in shares of Inogen by 2.8% in the first quarter. Royce & Associates LP now owns 259,455 shares of the medical technology company’s stock valued at $11,670,000 after buying an additional 7,000 shares in the last quarter. Menta Capital LLC purchased a new position in shares of Inogen during the first quarter valued at $446,000. Finally, Credit Agricole S A increased its position in shares of Inogen by 1,275.0% in the first quarter. Credit Agricole S A now owns 110,000 shares of the medical technology company’s stock valued at $4,948,000 after buying an additional 102,000 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Stock Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related stocks with our FREE daily email newsletter.